ArticleResearch (Washington, D.C.)2026
AI-Powered Discovery of Rosmarinic Acid as a Novel Ferroptosis Inhibitor for Ulcerative Colitis via Targeting the ALOX15-VDAC1 Axis.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited mechanism-based therapies, and ferroptosis-an iron-dependent lipid peroxidation-driven cell death-has emerged as a critical pathogenic event. Using a machine learning model that combines molecular fingerprints and transfer learning representations to screen for ALOX15 inhibitors, we identified rosmarinic acid (RA) from natural product libraries. RA exhibited high-affinity binding to ALOX15 and maintained stable complex conformation in molecular dynamics simulations. In dextran sulfate sodium-induced colitis mice and lipopolysaccharide-treated intestinal epithelial cells (IEC-6 and mouse colonic epithelial cell), RA alleviated disease activity index, colon shortening, histological damage, and barrier protein loss (ZO-1, Occludin, and Claudin-1). Mechanistically, RA suppressed ferroptosis by restoring GPX4, SLC7A11, and FTH1; reducing ACSL4, COX-2, and lipid reactive oxygen species (ROS); and lowering intracellular Fe
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.